scholarly journals Metabolic reprogramming and AMPKα1 pathway activation by caulerpin in colorectal cancer cells

2016 ◽  
Vol 50 (1) ◽  
pp. 161-172 ◽  
Author(s):  
Hua Yu ◽  
Huiqin Zhang ◽  
Mingjun Dong ◽  
Zhou Wu ◽  
Zhonglei Shen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Cells ◽  
Metabolic Reprogramming ◽  
Pathway Activation ◽  
Colorectal Cancer Cells

scholarly journals ANKRD22, a novel tumor microenvironment-induced mitochondrial protein promotes metabolic reprogramming of colorectal cancer cells

Theranostics ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 516-536
Author(s):  
Tianhui Pan ◽  
Jingwen Liu ◽  
Song Xu ◽  
Qiao Yu ◽  
Hongping Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Microenvironment ◽  
Cancer Cells ◽  
Mitochondrial Protein ◽  
Metabolic Reprogramming ◽  
Colorectal Cancer Cells

scholarly journals Inhibition of Liver Metastasis in Colorectal Cancer by Targeting IL-13/IL13Rα2 Binding Site with Specific Monoclonal Antibodies

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1731
Author(s):  
Marta Jaén ◽  
Rubén A. Bartolomé ◽  
Carmen Aizpurua ◽  
Ángela Martin-Regalado ◽  
J. Ignacio Imbaud ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibodies ◽  
Liver Metastasis ◽  
Cancer Cells ◽  
Metastatic Cancer ◽  
Receptor Internalization ◽  
Binding Motif ◽  
Pathway Activation ◽  
Colorectal Cancer Cells

Background: IL13Rα2 is reportedly a promising therapeutic target in different cancers. Still, no specific antagonists have reached the clinics yet. We investigated the use of a IL-13/IL13Rα2 binding motif, called D1, as a new target for the development of therapeutic monoclonal antibodies (mAbs) for colorectal cancer (CRC) metastasis. Methods: IL13Rα2 D1 peptides were prepared and used for immunization and antibody development. Antibodies were tested for inhibition of cellular invasion through Matrigel using CRC cell lines. Effects of the mAbs on cell signaling, receptor internalization and degradation were determined by western blot and flow cytometry. Swiss nude mice were used for survival analysis after treatment with IL13Rα2-specific mAbs and metastasis development. Results: IL13Rα2 D1 peptides were used to generate highly selective mAbs that blocked IL13/IL13Rα2-mediated SRC activation and cell invasion in colorectal cancer cells. Antibodies also provoked a significant reduction in cell adhesion and proliferation of metastatic cancer cells. Treatment with mAbs impaired the FAK, SRC and PI3K/AKT pathway activation. Blocking effectivity was shown to correlate with the cellular IL13Rα2 expression level. Despite mAb 5.5.4 partially blocked IL-13 mediated receptor internalization from the cancer cell surface it still promotes receptor degradation. Compared with other IL13Rα2-specific antibodies, 5.5.4 exhibited a superior efficacy to inhibit metastatic growth in vivo, providing a complete mouse survival in different conditions, including established metastasis. Conclusions: Monoclonal antibody 5.5.4 showed a highly selective blocking capacity for the interaction between IL-13 and IL13Rα2 and caused a complete inhibition of liver metastasis in IL13Rα2-positive colorectal cancer cells. This capacity might be potentially applicable to other IL13Rα2-expressing tumors.

Sign in / Sign up

Export Citation Format

Share Document